|
|
|
|
| LEADER |
00000cam a2200000 a 4500 |
| 001 |
3306178 |
| 005 |
20030526104400.0 |
| 008 |
980319s1998 pau 000 0 eng d |
| 003 |
ICU |
| 020 |
|
|
|a 039751848X
|
| 035 |
|
|
|a (OCoLC)38099903
|
| 040 |
|
|
|a NLM
|c NLM
|d VAM
|d MMU
|d IWA
|d OrLoB-B
|d OCoLC
|
| 049 |
|
|
|a CGUA
|
| 060 |
0 |
0 |
|a W1
|b AD684H v.76 1998
|
| 060 |
1 |
0 |
|a QV 85
|b A6273 1998
|
| 069 |
0 |
|
|a 9801200
|
| 090 |
|
|
|a RC374.C48
|b A575x 1998
|
| 245 |
0 |
0 |
|a Antiepileptic drug development /
|c editors, Jacqueline A. French, Marc A. Dichter, Ilo E. Leppik.
|
| 260 |
|
|
|a Philadelphia, Pa. :
|b Lippincott-Raven Publishers,
|c 1998.
|
| 300 |
|
|
|a xvii, 276 p. :
|b ill.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|0 http://id.loc.gov/vocabulary/contentTypes/txt
|
| 337 |
|
|
|a unmediated
|b n
|2 rdamedia
|0 http://id.loc.gov/vocabulary/mediaTypes/n
|
| 338 |
|
|
|a volume
|b nc
|2 rdacarrier
|0 http://id.loc.gov/vocabulary/carriers/nc
|
| 440 |
|
0 |
|a Advances in neurology
|v v. 76
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 505 |
0 |
0 |
|g I.
|t Preclinical Antiepileptic Drug Development.
|g 1.
|t Mechanism of Action of New Antiepileptic Drugs /
|r Marc A. Dichter.
|g 2.
|t Mechanism-Specific Pathways for New Antiepileptic Drug Discovery /
|r Michael A. Rogawski.
|g 3.
|t The National Institutes of Health Anticonvulsant Drug Development Program: Screening for Efficacy /
|r H. Steve White, Harold H. Wolf and Jose H. Woodhead, [et al.].
|g 4.
|t Pharmaceutical Industry Screening for New Antiepileptic Drugs /
|r Charles P. Taylor and James L. Marks.
|g 5.
|t Metabolic Enzymes and Antiepileptic Drug Interactions /
|r Rene Levy and Gary G. Mather --
|g II.
|t Clinical Drug Development.
|g 6.
|t New Drugs for Persons with Epilepsy /
|r David E. Blum.
|g 7.
|t AED Doses: From Animals to Humans /
|r Ilo E. Leppik.
|g 8.
|t Assessing Pharmacokinetic and Pharmacodynamic Drug Interactions in Clinical Trials of Antiepileptic Drugs /
|r Ross A. Reife.
|g 9.
|t Novel Methods for Studying New Antiepileptic Drug Pharmacology /
|r Richard H. Mattson, Richard D. Scheyer and Ognen A. C. Petroff [et al.].
|g 10.
|t The Art of Antiepileptic Trial Design /
|r Jacqueline A. French.
|g 11.
|t Reanalysis of Existing Trial Data: What Can Be Learned /
|r J. Todd Sahlroot and Gordon W. Pledger.
|g 12.
|t Monotherapy Trials /
|r Elizabeth A. Garofalo.
|g 13.
|t The Impact of Foreign Data on a New Drug Application /
|r Hal Galbraith and Steven D. Walker --
|g III.
|t Special Populations.
|g 14.
|t Issues for Women in Antiepileptic Drug Development /
|r Martha J. Morrell.
|g 15.
|t Antiepileptic Drug Trials in Children and Adolescents: Is There a Need? /
|r Jeffrey R. Buchhalter.
|g 16.
|t Pediatric Trials: Practical Issues. Special Populations and Trial Design /
|r John M. Pellock.
|g 17.
|t Clinical Trials for Status Epilepticus /
|r David M. Treiman.
|g 18.
|t Clinical Trials for Seizure Prevention /
|r Nancy R. Temkin, Sureyya S. Dikmen and H. Richard Winn --
|g IV.
|t Special Issues.
|g 19.
|t Alternate Endpoints for Seizure Measurement /
|r Joyce A. Cramer.
|g 20.
|t Alternate Endpoints: Studies in Quality of Life and Health Economics of Epilepsy /
|r Azmi A. Nabulsi and Karrar H. Ali.
|g 21.
|t Alternate Endpoint: EEG Assessment of Antiepileptic Drug Efficacy and Toxicity /
|r Eli M. Mizrahi.
|g 22.
|t Routine Measurement of New Antiepileptic Drug Concentrations: A Critique and a Prediction /
|r Martin J. Brodie.
|g 23.
|t Cognitive and Behavioral Assessments in AED Trials /
|r Kimford J. Meador.
|g 24.
|t Economic Factors in the Development of New Antiepileptic Drugs /
|r Roger J. Porter.
|g 25.
|t Recent Issues and Considerations in the Regulation of Antiepileptic Drugs /
|r Russel G. Katz.
|g 26.
|t Ethical and Institutional Review Board Issues /
|r Brett E. Skolnick.
|g 27.
|t Postmarketing Studies /
|r Neil Sussman.
|
| 650 |
|
0 |
|a Anticonvulsants.
|0 http://id.loc.gov/authorities/subjects/sh85005657
|
| 650 |
|
0 |
|a Epilepsy
|x Chemotherapy.
|0 http://id.loc.gov/authorities/subjects/sh2008119833
|
| 650 |
1 |
2 |
|a Anticonvulsants
|x pharmacology.
|
| 650 |
2 |
2 |
|a Epilepsy
|x drug therapy.
|
| 650 |
2 |
2 |
|a Drug Evaluation, Preclinical
|x methods.
|
| 650 |
2 |
2 |
|a Clinical Trials
|x methods.
|
| 650 |
2 |
2 |
|a Research Design.
|
| 650 |
|
7 |
|a Anticonvulsants.
|2 fast
|0 http://id.worldcat.org/fast/fst00810472
|
| 650 |
|
7 |
|a Epilepsy
|x Chemotherapy.
|2 fast
|0 http://id.worldcat.org/fast/fst00914186
|
| 700 |
1 |
|
|a French, Jacqueline A.
|0 http://id.loc.gov/authorities/names/n93801861
|1 http://viaf.org/viaf/311803149
|
| 700 |
1 |
|
|a Dichter, Marc A.
|0 http://id.loc.gov/authorities/names/n88046132
|1 http://viaf.org/viaf/77858551
|
| 700 |
1 |
|
|a Leppik, Ilo E.
|0 http://id.loc.gov/authorities/names/n88046156
|1 http://viaf.org/viaf/33540527
|
| 901 |
|
|
|a ToCBNA
|a Analytic
|
| 903 |
|
|
|a HeVa
|
| 903 |
|
|
|a Hathi
|
| 929 |
|
|
|a cat
|
| 999 |
f |
f |
|i 21a2f05c-2b4d-54fc-b974-576f180bf853
|s 7dd60833-0bb4-5d92-b403-e7a629bf5799
|
| 928 |
|
|
|t Library of Congress classification
|a RC331.A25 v.76
|l ASR
|c ASR-SciASR
|i 6187975
|
| 927 |
|
|
|t Library of Congress classification
|a RC331.A25 v.76
|l ASR
|c ASR-SciASR
|g Analytic
|e CRERAR
|b A47731828
|i 5681832
|
